Journal of Depression and Anxiety
Open Access

Reiji Yoshimura

Publications

• Research Article
  Can Plasma Level of 3-methoxy-4-hydroxyphenylglycol Predict the Response for Selective Serotonin Reuptake Inhibitor and Serotonin Noradrenaline Reuptake Inhibitor in Major Depressive Disorder?
  Author(s): Reiji Yoshimura, Asuka Katsuki, Kiyokazu Atake, Ryohei Igata, Yuki Konishi, and Hikaru Hori Reiji Yoshimura, Asuka Katsuki, Kiyokazu Atake, Ryohei Igata, Yuki Konishi, and Hikaru Hori
  
  We investigated whether the plasma level of 3-methoxy-4-hydroxyphenylglycol (MHPG) could be used to predict the response to selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenaline reuptake inhibitors (SNRIs) in patients with major depressive disorder (MDD). Patients with MDD diagnosed by DSM-IV-TR were enrolled in the present study. Two hundred and forty participants were treated monotherapy with the SSRI paroxetine (n=81), selective serotonin and norepinephrine reuptake inhibitor antidepressant (SSNRI) duloxetine (n=49), the SNRI milnacipran (n=48), the SSRI fluvoxamine (n=63), or the SSRI escitalopram (n=27). The severity of depressive state was evaluated with the 17-item of Hamilton Rating Scale for Depression (HAMD17). The end-point point of the present study was week 8. Patients whose HAMD17 scores decreased ≥ 50% were defined as responders; others were non.. View More»
  DOI: 10.4172/2167-1044.1000269

  Abstract PDF

Relevant Topics